Page 138 - 2019年8月第30卷第16期

[17] MING LK，TIEN YL，YAW BH ，et al. The evaluation of [27] 崔占苹.慢性阻塞性肺疾病临床治疗进展[J].中国处方
β-adrenoceptor blocking agents in patients with COPD 药，2017，15（9）：9-11.
and congestive heart failure：a nationwide study[J]. Int J [28] CAZZOLA M，CALZETTA L，BARNES PJ，et al. Effica-
Chron Obstruct Pulmon Dis，2017，8（12）：2573-2581. cy and safety profile of xanthines in COPD：a network
[18] NEEF PA，BURRELL LM，MCDONALD CF，et al. Com- meta-analysis[J]. Eur Respir Rev，2018，27（148）：1-11.
mencement of cardioselective beta-blockers during hospi- [29] YEGANEH B，WIECHEC E，ANDE SR，et al. Targeting
talisation for acute exacerbations of chronic obstructive the mevalonate cascade as a new therapeutic approach in
pulmonary disease[J]. Intern Med J，2017，6（11）：977- heart disease，cancer and pulmonary disease[J]. Phar Ther，
984. 2014，143（1）：87-110.
[19] STEFAN MS，ROTHBERG MB，PRIYA A，et al. Associa- [30] LEI FS，SIN DD. COPD and cardiovascular diseases：
tion between β-blocker therapy and outcomes in patients now is the time for action! [J]. Thorax，2018，73（9）：53-
hospitalised with acute exacerbations of chronic obstruc- 56.
tive lung disease with underlying ischaemic heart disease， [31] SANJA M，JOZSEF P，SANJA PG，et al. Cytokines and
heart failure or hypertension[J]. Thorax，2012，67（11）： statin therapy in chronic obstructive pulmonary disease pa-
977-984. tients[J]. Scan J Clin Lab Inv，2018，10（78）：1-6.
[20] CHEN J，RADFORD MJ，WANG Y，et al. Effectiveness [32] AMARIEI DE，REED RM. The role of statins in chronic
of beta-blocker therapy after acute myocardial infarction obstructive pulmonary disease：is cardiovascular disease
in elderly patients with chronic obstructive pulmonary dis- the common denominator? [J]. Curr Opin Pulm Med，
ease or asthma[J]. J Am Coll Cardiol，2001，37（7）：1950- 2019，25（2）：1-6.
1956. [33] REA F，CALUSI G，FRANCHI M，et al. Adherence of el-
[21] SHORT PM，LIPWORTH SI，ELDER DH，et al. Effect of derly patients with cardiovascular disease to statins and
beta blockers in treatment of chronic obstructive pulmo- the risk of exacerbation of chronic obstructive pulmonary
nary disease：a retrospective cohort study[J]. BMJ，2018， disease：evidence from an italian real-world investigation
18（1）：124-131. [J]. Drugs Aging，2018，35（12）：1099-1108.
[22] MORGAN AD，ZAKERI R，QUINT JK. Defining the rela- [34] SU TH，CHANG SH，KUO CF，et al. β-blockers after acute
tionship between COPD and CVD：what are the implica- myocardial infarction in patients with chronic obstructive
tions for clinical practice? [J]. Ther Adv Respir Dis，2018， pulmonary disease：a nationwide population-based obser-
12（10）：524-540. vational study[J]. PLoS One，2019，14（3）：187-201.
[23] SU VY，CHANG YS，HU YW，et al. Carvedilol，biso- [35] MAGNUS P EKSTRÖM，HERMANSSON AB，KERST-
prolol，and metoprolol use in patients with coexistent IN E STRÖM. Effects of cardiovascular drugs on mortali-
heart failure and chronic obstructive pulmonary disease[J]. ty in severe chronic obstructive pulmonary disease[J].Am
Medicine：Baltimore，2016，95（5）：2427-2434. J Respir Crit Care Med，2013，187（7）：715-720.
[24] LAHOUSSE L，VERHAMME KM，STRICKER BH， [36] PAVASINI R，BISCAGLIA S，D’ASCENZO F，et al. Anti-
et al. Cardiac effects of current treatments of chronic ob- platelet treatment reduces all-cause mortality in COPD pa-
structive pulmonary disease[J]. Respir Med，2016，4（2）： tients：a systematic review and Meta-analysis[J]. Int J
149-164. Chron Obstruct Pulmon Dis，2015，13（4）：1-6.
[25] CRINER GJ，CELLI BR. Failure of low-dose theophylline [37] KUNADIAN V，CHAN D，ALI H，et al. Antiplatelet thera-
to prevent exacerbations in patients with COPD[J].JAMA， py in the primary prevention of cardiovascular disease in
2018，320（15）：1541-1542. patients with chronic obstructive pulmonary disease：pro-
[26] WILAIRAT P，KENGKLA K，THAYAWIWAT C，et al. tocol of a randomised controlled proof-of-concept trial
Clinical outcomes of theophylline use as add-on therapy in （APPLE COPD-ICON 2）[J]. BMJ Open，2018，8（5）：
patients with chronic obstructivepulmonary disease：a pro- 713-724.
pensity score matching analysis[J]. Chron Respir Dis，2019， （收稿日期：2019-04-15 修回日期：2019-07-23）
16（2）：5694-5708. （编辑：孙 冰）

中国药房 2019年第30卷第16期 China Pharmacy 2019 Vol. 30 No. 16 ·2293 ·